Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches

References

• Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. CN. 2011;9:409–416.
   Web of Science ®Google Scholar
• Losy J. Is MS an inflammatory or primary degenerative disease? J Neural Transm (Vienna). 2013;120:1459–1462.
   PubMed Web of Science ®Google Scholar
• Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83:1022–1024.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391:1622–1636.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–286.
   PubMed Web of Science ®Google Scholar
• Menon S, Shirani A, Zhao Y, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1192–1198.
   PubMed Web of Science ®Google Scholar
• Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11:379–389.
   PubMed Web of Science ®Google Scholar
• Fernandez O. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Mult Scler Relat Disord. 2017;17:75–83.
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405–415.
   PubMed Web of Science ®Google Scholar
• Derfuss T, Bergvall NK, Sfikas N, et al. Efficacy of fingolimod in patients with highly active relapsing–remitting multiple sclerosis. Curr Med Res Opin. 2015;31:1687–1691.
   PubMed Web of Science ®Google Scholar
• Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012;11:420–428.
   PubMed Web of Science ®Google Scholar
• Cohen BA, Khan O, Jeffery DR, et al. Identifying and treating patients with suboptimal responses. Neurology. 2004;63:S33–S40.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Cohen B, Dhib-Jalbut S, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin. 2009;25:2459–2470.
   PubMed Web of Science ®Google Scholar
• Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13:257–267.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–426.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. Clinical efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis (RRMS): final results from the 120-week phase IIIb extension trial to the CLARITY study (P3.028). Neurology. 2016;86(16 Suppl.):P3.028.
   Google Scholar
• Giovannoni G, Soelberg Sorensen P, Cook S, et al. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler. 2018. DOI: 10.1177/1352458518771875.
   Web of Science ®Google Scholar
• Kalincik T. Comparisons of therapies in different scenarios help complete the puzzle. Mult Scler. 2018;24:694–695.
   PubMed Web of Science ®Google Scholar
• Siddiqui MK, Khurana IS, Budhia S, et al. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. Curr Med Res Opin. 2018;34:1361–1371.
   PubMed Web of Science ®Google Scholar
• Huisman E, Papadimitropoulou K, Jarrett J, et al. Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open. 2017;7:e013430.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE), Single technology appraisal (STA). Specification for manufacturer/sponsor submission of evidence, June 2012 [cited 2017 Jan 5]. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Specification-for-manufacturer-sponsor-submission-of-evidence-June-2012.doc.
   Google Scholar
• Haute Autorite de Sante (HAS). Guide d’analyse de la litterature et gradation des recommandations [Analysis of the literature and recommendations grading guide], January 2000 [cited 2017 Jan]. Available from: http://www.has-sante.fr/portail/jcms/c_266796/fr/analyse-litterature-medicale-guide-methodologique-2000pdf.
   Google Scholar
• Gemeinsamer Bundesausschuss (G-BA). The benefit assessment of pharmaceuticals in accordance with the German Social Code, Book Five (SGB V), section 35a; [cited 2017 Jan 5]. Available from: https://www.g-ba.de/english/benefitassessment/.
   Google Scholar
• Dias S, Sutton AJ, Welton NJ, et al. NICE decision support unit technical support documents. Heterogeneity: subgroups, meta-regression, bias and bias-adjustment. London, UK: National Institute for Health and Care Excellence (NICE); 2012.
   Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38:200–211.
   PubMed Web of Science ®Google Scholar
• Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013;(6):CD008933. DOI: 10.1002/14651858.CD008933.pub2.
   PubMed Web of Science ®Google Scholar
• Tolley K, Hutchinson M, You X, et al. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing–remitting multiple sclerosis. Plos One. 2015;10:e0127960.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819–1828.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786–1801.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Jokubaitis V, Spelman T, et al. Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis. Mult Scler. 2018;24:1617–1626.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, De Stefano N, Sormani MP, et al. Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat Disord. 2015;4:460–469.
   PubMed Web of Science ®Google Scholar